Table 2.
Clinical Outcome of the Patients
| PCR-Positive (n = 223) |
PCR-Negative (n = 126) |
P | |
|---|---|---|---|
| Time to defervescence, days | 4.3 ± 3.3 | 1.9 ± 1.6 | .02 |
| Tocilizumab treatment, n (%) | 19 (8.5) | 0 | .003 |
| Anticoagulant treatment, n (%) | 136 (61.0) | 52 (41.3) | .001 |
| Systemic glucocorticoid treatment, n (%) | 21 (9.4) | 11 (8.7) | .93 |
| Admission to the ICU, n (%) | 46 (20.6) | 12 (9.6) | .023 |
| Supplemental oxygen, n (%)* | 97 (43.5) | 27 (21.4) | <.001 |
| Non-invasive ventilation, n (%)** | 25 (11.2) | 4 (3.2) | .03 |
| Invasive ventilation, n (%) | 25 (11.2) | 10 (7.9) | .59 |
| Length of hospital stay, days | 9.7 ± 5.9 | 5.0 ± 5.0 | <.001 |
| In-hospital mortality, n (%) | 27 (12.1) | 13 (10.3) | .83 |
*This refers to the need for supplemental oxygen any time during the hospitalization. The numbers include the patients who also required invasive and/or non-invasive ventilation.
**Patients requiring non-invasive ventilation first, who then had to be intubated and received invasive ventilation, were counted as “invasive ventilation” only.